Jon Faiz Kayyem, Director at Inhibrx Biosciences, Inc. (INBX), bought 107,186 shares at $14.23 ($1.5M) on 2024-11-19, disclosed to the SEC on 2024-11-22.
Open-market purchase of $1.5M INBX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.23 | 34,843 | $496K | 32.5% |
| 2 | $14.23 | 34,843 | $496K | 32.5% |
| 3 | $14.19 | 18,750 | $266K | 17.5% |
| 4 | $14.19 | 18,750 | $266K | 17.5% |
| Total | $14.22 avg | 107,186 | $1.5M | 100% |
| Filing → |
| INBX | BUY | 2026-09-08 | $568K | — | Filing → |
| INBX | BUY | 2024-06-07 | $2.0M | — | Filing → |
| INBX | BUY | 2024-06-04 | $9.9M | — | Filing → |